Jack B. Campbell
Eli Lilly and Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jack B. Campbell.
Archive | 2012
Susan L. Cutter; Balgis Osman-Elasha; Jack B. Campbell; So-Min Cheong; Sabrina McCormick; Roger Pulwarty; Seree Supratid; Gina Ziervogel; Eduardo Calvo; Khamaldin Daud Mutabazi; Alex Arnall; Margaret Arnold; Joanne Linnerooth Bayer; Hans-Georg Bohle; Christopher T. Emrich; Stéphane Hallegatte; Bettina Koelle; Noel Oettle; Emily Polack; Nicola Ranger; Stephan Rist; Pablo Suarez; Gustavo Wilches-Chaux
Disasters are most acutely experienced at the local level (high agreement, robust evidence). The reality of disasters in terms of loss of life and property occurs in local places and to local people. These localized impacts can then cascade to have national and international consequences. In this chapter, local refers to a range of places, social groupings, experience, management, institutions, conditions, and sets of knowledge that exist at a sub-national scale. [5.1] Developing strategies for disaster risk management in the context of climate change requires a range of approaches, informed by and customized to specific local circumstances (high agreement, robust evidence). These differences and the context (national to global, urban to rural) in which they are situated shape local vulnerability and local impacts. [5.1] The impacts of climate extremes and weather events may threaten human security at the local level (high agreement, medium evidence). Vulnerability at the local level is attributed to social, political, and economic conditions and drivers including localized environmental degradation and climate change. Addressing disaster risk and climate extremes at the local level requires attention to much wider issues relating to sustainable development. [5.1] While structural measures provide some protection from disasters, they may also create a false sense of safety (high agreement, robust evidence). Such measures result in increased property development, heightened population density, and more disaster exposure. Current regulations and design levels for structural measures may be inadequate under conditions of climate change.
Tetrahedron | 1989
Norris E. Allen; Donald B. Boyd; Jack B. Campbell; Jack B. Deeter; Thomas K. Elzey; Bennie Joe Foster; Lowell D. Hatfield; Joseph N. Hobbs; William Joseph Hornback; David C. Hunden; Noel D. Jones; Michael Dean Kinnick; John M. Morin; John E. Munroe; John K. Swartzendruber; David G. Vogt
Abstract Computational chemistry made possible the prediction of the three-dimensional structures of γ-lactam analogues of penems and carbapenems before the analogues were made. Molecular superpositioning showed that these novel structures with a 7β-acylamino side-chain present the pharmacophoric groups in close spatial similarity to the groups in biologically active cephalosporin and penicillin antibiotics. This suggests that 8-oxo-7-acylamino-1-azabicyclo[3.3.0]-oct-2-ene-2-carboxylates and the 4-thia-analogues can be accommodated in the same active sites of essential bacterial penicillin-binding proteins where cephalosporins and penicillins are recognized. The syntheses of these compounds are reported. The γ-lactams exhibit low, but detectable levels of antibacterial activity and suggest promise that substantial activity can be achieved with other γ-lactams.
Bioorganic & Medicinal Chemistry Letters | 1995
John E. Munroe; William Joseph Hornback; Jack B. Campbell; Michael A. Ouellette; Steve D. Hatch; Mark A. Muesing; Mary Ann Wiskerchen; Angela J. Baxter; Ken Su; Kristina M. Campanale
Abstract Replacement of the decahydroisoquinoline group contained in Ro 31-8959 by a cis -octahydrothienopyridine moiety has provided a high affinity hydroxyethylamine isostere for use in HIV-1 protease inhibitors. Further gains in potency have been realized by incorporation of a sulfur atom into the P 1 benzyl group. Modification by a key P 2 ligand provided LY316440, a potent, orally absorbed inhibitor of HIV-1 protease.
Journal of Medicinal Chemistry | 1996
James A. Monn; Matthew John Valli; Bryan G. Johnson; Craig R. Salhoff; Rebecca A. Wright; Trevor J. Howe; Ann Bond; David Lodge; Larry A. Spangle; Jonathan W. Paschal; Jack B. Campbell; Kelly I. Griffey; Joseph P. Tizzano; Darryle D. Schoepp
Journal of Medicinal Chemistry | 1992
Paul L. Ornstein; Darryle D. Schoepp; M. Brian Arnold; Nancy K. Augenstein; David Lodge; John D. Millar; John Chambers; Jack B. Campbell; Jonathan W. Paschal
Journal of Medicinal Chemistry | 2000
John Joseph Masters; Jeffry Bernard Franciskovich; Jennifer M. Tinsley; Charles S. Campbell; Jack B. Campbell; Trelia J. Craft; Larry L. Froelich; Donetta S. Gifford-Moore; Lynne A. Hay; David K. Herron; Valentine J. Klimkowski; Kenneth D. Kurz; James T. Metz; Andrew Michael Ratz; Robert Theodore Shuman; Gerald F. Smith; Tommy Smith; Richard D. Towner; Michael Robert Wiley; Alexander Wilson; Ying K. Yee
Journal of Heterocyclic Chemistry | 1986
Jack B. Campbell; James Michael Greene; Edward Ralph Lavagnino; D. N. Gardner; Andrew Joseph Pike; J. Snoddy; Edward C. Taylor
Archive | 1980
Edward Ralph Lavagnino; Andrew Joseph Pike; Jack B. Campbell
Archive | 1985
Jack B. Campbell; Edward Ralph Lavagnino; Andrew Joseph Pike
Archive | 1978
Jack B. Campbell